Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D) (AWARE-CKD)
Awareness of Diagnosis and Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians know about the different treatment options available; and how they use this knowledge to treat their patients successfully. Additionally, researchers want to gather information about patient's awareness of their disease and which criteria they consider important for their treatment of the disease.
The study will survey a total of 150 patients with type 2 diabetes: 50 patients with mild CKD; 50 patients with moderate CKD; and 50 patients with severe CKD. Patients eligible for this study can be male or female and should be at least 18 years old. In addition, a total of 150 physicians will be surveyed. Physicians eligible for this study may be general practitioners, endocrinologist, or nephrologists.
研究概览
详细说明
The primary objective in this study is to assess the awareness, values and preferences of patients and physicians with respect to the risks, consequences and management of chronic kidney disease (CKD) in patients with type 2 diabetes.
Secondary objectives aim to assess awareness of available CKD treatments, referral tools and communication between patients and physicians.
Both patients and physicians will complete a survey that consists of various questions regarding the knowledge of disease, values and treatments, patient-physician interaction, physician referral tools and disease risk management.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Multiple Locations、加拿大
- Many facilities
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
For patient cohort:
- Diagnosis of type 2 diabetes
- eGFR < 60 ml/min per 1.73 m2 (measured within the last year) OR eGFR ≥ 60 ml/min per 1.73 m2 and uACR ≥ 2 (measured within the last year)
- No documented non-diabetic etiology for renal disease
For physician cohort:
- Licensed general practitioner, endocrinologist or nephrologist
- Currently providing care for patients with chronic kidney disease and type 2 diabetes
Exclusion Criteria:
- Patients with chronic kidney disease and type 2 diabetes who are physicians
- Physicians with chronic kidney disease and type 2 diabetes
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
CKD-Patients
Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
|
无干预，观察性研究
|
|
Physicians treating CKD
Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
|
无干预，观察性研究
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Awareness of chronic kidney disease in T2D
大体时间：1 day
|
Awareness will be summarized descriptively based on various survey questions.
|
1 day
|
|
Values regarding chronic kidney disease in T2D
大体时间：1 day
|
Values regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
|
1 day
|
|
Preferences regarding chronic kidney disease in T2D
大体时间：1 day
|
Preferences regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
|
1 day
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Awareness of available treatments for chronic kidney disease in T2D
大体时间：1 day
|
Awareness of available treatments will be summarized descriptively based on various survey questions.
|
1 day
|
|
Physician awareness of available referral tools for the management of chronic kidney disease in T2D
大体时间：1 day
|
Physician cohort only.
Referral tools may comprise of various standard guidelines (e.g.
KidneyWise, KDIGO guidelines, Diabetes Canada guidelines).
A higher number of referral tools known by physicians indicates a better awareness of CKD referral tools.
|
1 day
|
|
Time point of communicated CKD diagnosis
大体时间：1 day
|
1 day
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 21225
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.